China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO) of 16.35 million shares on the Hong Kong Stock Exchange. The share price is expected to range from HKD 22.96 to 26.24 (USD 2.94 to USD 3.36) per share, with a maximum gross take-home of around USD 55 million. The IPO is scheduled to go ahead on December 15.
Company Profile and Pipeline
Founded in 2014, 3D Medicines has a robust pipeline of 12 novel cancer therapies, with eight currently at clinical or commercialization stages. Among these, envafolimab, the world’s first PD-L1 single-domain antibody and human IgG1 Fc fusion protein capable of being injected subcutaneously, has been approved for marketing in China. The drug generated RMB 161.1 million (USD 22.4 million) in sales during the first five months of 2022. It is used to treat adult patients with advanced solid tumors with unresectable or microsatellite instability-high (MSI-H) or deficient mismatch repair gene (dMMR), an indication affecting 146,000 people in 2021 and expected to affect 186,000 people by 2030. The company also has seven other drugs in clinical stages, including a polypeptide cancer vaccine, a TKI inhibitor, and a CD47 monoclonal antibody.
Financial Performance and Future Plans
3D Medicines recorded losses of RMB 1.461 billion (USD 203.6 million) in 2021 and RMB 293.4 million (USD 40.9 million) in the first five months of 2022, primarily due to research and development expenses, administrative expenditures, and fair value loss of preferred shares. The company plans to use the IPO proceeds to enhance its in-house discovery capabilities and conduct more clinical trials for in-licensed drugs. Additionally, 3D Medicines is establishing an internal manufacturing plant in Xuzhou, Jiangsu province, with an expected total production capacity of 6,000L by 2024.-Fineline Info & Tech
